November 9, 2011 — Volcano Corp. announced results from the ADVISE (ADenosine Vasodilator Independent Stenosis Evaluation) clinical trial will be presented in a Late-Breaking Session at Transcatheter Cardiovascular Therapeutics (TCT) 2011. The event is taking place from Nov. 7-11 in San Francisco.

November 9, 2011 – Abiomed, a provider of heart support technologies, announced results of an economic study at the annual 2011 Transcatheter Cardiovascular Therapeutics (TCT) conference. The economic study demonstrated that Impella significantly reduced major adverse events at an incremental cost per quality-adjusted life year considered to be cost-effective for advanced cardiovascular technologies.  Quality of life benefits included an increase in ejection fraction of over 20 percent and an improvement in New York Heart Association (NYHA) Class III and Class IV heart failure of over 50 percent.

November 9, 2011 — Janssen Pharmaceuticals Inc. announced the U.S. Food and Drug Administration (FDA) has approved Xarelto to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (AFib). Xarelto is an oral anticoagulant that offers once-daily dosing without the need for routine blood monitoring.

November 9, 2011 – Siemens Healthcare announced that the company has entered into a definitive agreement to acquire all issued and outstanding equity of MobileMD Inc., of Yardley, Pa., a provider of health information exchange (HIE) solutions.

November 9, 2011 – A group of states and vendors focused on eliminating the barriers to sharing electronic health records (EHRs) issued a set of technical specifications to standardize connections between healthcare providers, health information exchanges (HIEs) and other data-sharing partners.

November 9, 2011 – PETNET Solutions Inc., a wholly owned subsidiary of Siemens Medical Solutions USA Inc., has entered into a nationwide commercial agreement with Eli Lilly and Company that grants Siemens PETNET Solutions the right to manufacture and distribute Lilly’s molecular imaging agent, which is currently under review by the U.S. Food and Drug Administration (FDA) for positron emission tomography (PET) imaging.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now